Applied Clinical Trials-06-01-2018

A look at home and dosing site considerations.

Editor-in-Chief Lisa Henderson speak about therapeutic needs, rare diseases in children, and the SCORR Marketing survey on innovative or flexible trial designs.

Findings from a new ACT and SCORR Marketing survey reveal the most actively used flexible design approaches in clinical research-many with application in rare disease.

Leader of one longtime CRO discusses the marked changes in clinical trial practice from past to present-and the company’s unique focus.

Jill Wechsler details the continued rise of incorporating the “patient experience” in drug development measures.

Exploring three distinct patient partnership models to help researchers assess which methods of engagement could work best for their clinical programs.

With more common cancers now increasingly broken down by specific genomic defects, the future of research for any cancer is entirely, and unequivocally, molecular.

Outlining the unique pharmacokinetic factors that should be considered when designing and running early stage clinical trials for monoclonal antibodies.

Sobering statistics collected on clinical trial execution point to the eventual convergence of healthcare and clinical research operating environments.

Peter O’Donnell explores the convergence of policy and science in new vaccine R&D pursuits in Europe.

Click the title above to open the Applied Clinical Trials June 2018 issue in an interactive PDF format.

Case study demonstrates that site activation is a key driver in determining patient enrollment cycle time.